Lilly tests second COVID antibody
The Indianapolis drugmaker also said it expects to begin dosing patients in a complementary clinical study in the U.S. in the coming days.
Eli Lilly and Co.
Articles
Eli Lilly begins human testing on potential COVID-19 treatment
Dr. Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories, said Lilly has already started “large-scale manufacturing” of the potential treatment.
Lilly teams with Chinese biotech to develop COVID-19 antibody
The partnership marks at least the fourth program Lilly is pursuing to find treatments for COVID-19, a disease that has claimed more than 249,000 lives worldwide, including more than 68,000 in the U.S.
Reports that Trump may fire HHS leader Azar are ‘fake news,’ president says
One senior administration official with knowledge of the discussions said Trump has no deep affection for Alex Azar but is unlikely to change Health and Human Services secretaries as the coronavirus continues to rage.
Lilly bracing for COVID-19-related headwinds this year
The Indianapolis-based drugmaker, which reported quarterly earnings Thursday, warned it could feel the effects of rising unemployment, a decrease in new prescriptions, and downward pricing pressure from government health care systems.
Richard Wood, CEO of Lilly during transformational era, dies at 93
Eli Lilly and Co.’s breakthroughs during Wood’s 18-year tenure included biosynthetic insulin and the category-smashing antidepressant Prozac.
Court rejects Lilly’s challenge of competitor’s patents on migraine drug
Eli Lilly and Co.’s treatment Emgality and Teva Pharmaceutical’s drug Ajovy were approved within months of each other in 2018.
Lilly expands drive-thru COVID-19 testing to essential workers, vulnerable seniors
The decision means perhaps tens of thousands of additional people can get tested at Lilly’s drive-thru, including people who work in grocery stores, pharmacies, banks and other places listed by the state as essential.
Lilly teams with British startup to develop autoimmune medicines
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.
Pharma giant Lilly to help Indiana health officials with COVID-19 testing
State officials have taken sharp criticism in the last week for the slow pace of testing. Through Tuesday, the Indiana State Department of Health had conducted 193 tests, out of which 39 were presumed positive.
Companies are seeking to reduce their environmental impacts and increase sustainability
Increasingly, as the planet warms, pressure is building from environmentalists, investors, consumers and the general public for corporate America to do something about it.
Lilly teams with Canadian biotech in race to find treatment for COVID-19
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Eli Lilly asking employees to work from home due to coronavirus
Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
Indiana firms restrict travel, postpone product intros, distribute hand sanitizer in reaction to coronavirus
A growing number of employers have restricted international travel and are now considering what they might need to do within the U.S.
Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Lilly to build $470M manufacturing plant in North Carolina
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
Lilly kills R&D deal in speed bump on quest to become big cancer player
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
$1.1B acquisition would give Lilly more skin in immunology game
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
Lilly wins another patent infringement case over cancer drug Alimta
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.